An objective of the present invention is to provide a means for enablingcancer immunotherapy that targets approximately 30% of various cancer patientsthathighly express forkhead box M1 (FOXM1) among the Japanese, by identifyingFOXM1-derived peptides that can activate cancer cell-damaging human killer Tcellsby binding to HLA-A2. The present invention provides a peptide of (A) or (B)below:(A) a peptide including the amino acid sequence of any one of SEQ ID NOs:1 to 3；(B) a peptide which includes the amino acid sequence of any one of SEQ IDNOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted,deleted,inserted, and/or added, and wherein the peptide shows cytotoxic (killer) Tcell-inducing activity.
